Picture of Anteris Technologies Global logo

AVR — Anteris Technologies Global Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Momentum

Relative Strength (%)
1m-22.5%
3m-21.76%
6m+8.77%
1yr+20.37%
Volume Change (%)
10d/3m-60.39%
Price vs... (%)
52w High-41.76%
50d MA-21.35%
200d MA-12.46%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-41.8%
Return on Equity-75.1%
Operating Margin-4738.36%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202631st Dec 2027
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2026 / 2027

Blurred out image of Anteris Technologies Global EPS forecast chart

Profile Summary

Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company's ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.

Directors

    Last Annual
    December 31st, 2025
    Last Interim
    June 30th, 2026
    Incorporated
    January 29th, 2024
    Public Since
    December 13th, 2024
    No. of Shareholders
    28
    No. of Employees
    174
    Sector
    Healthcare Equipment & Supplies
    Industry
    Healthcare
    Exchange
    au flag iconAustralian Stock Exchange - SEATS
    Shares in Issue
    97,458,474

    AVR Share Price Performance

    Similar to AVR

    Picture of 4DMedical logo

    4DMedical

    au flag iconAustralian Stock Exchange - SEATS

    Picture of Adheris Health logo

    Adheris Health

    au flag iconAustralian Stock Exchange - SEATS

    Picture of Adherium logo

    Adherium

    au flag iconAustralian Stock Exchange - SEATS

    Picture of Ansell logo

    Ansell

    au flag iconAustralian Stock Exchange - SEATS

    Picture of Aroa Biosurgery logo

    Aroa Biosurgery

    au flag iconAustralian Stock Exchange - SEATS

    FAQ